Robuta

https://www.elsevier.es/en-revista-annals-hepatology-16-articulo-blood-pressure-stratification-for-predicting-S1665268122002344
Introduction and ObjectivesThe optimal blood pressure (BP) range for patients with metabolic
blood pressureliver fibrosisstratificationpredictingrisk
https://www.uam.es/uam/investigacion/proyectos-investigacion/erc/mitocure
Molecular and metabolic mechanisms underlying mitochondrial dysfunction
mitochondrial dysfunctionmolecularmetabolicmechanismsunderlying
https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1469492/full
Non-alcoholic fatty liver disease (NAFLD), now known as metabolic-associated steatotic liver disease (MASLD), is the most common liver disease worldwide, wit...
cardiovascular diseasemetabolic dysfunctionfrontiersdriversassociated
https://www.ndtv.com/health/fathers-exposure-to-microplastics-may-increase-metabolic-dysfunction-and-diabetes-risk-in-daughters-finds-study-10031924
A fathers exposure to microplastics can trigger metabolic dysfunctions in children, with daughters more at risk of developing diabetes, according to animal...
metabolic dysfunctionfatherexposuremicroplasticsmay
https://www.ajmc.com/view/assessing-the-complex-interplay-between-metabolic-dysfunction-and-rheumatoid-arthritis
Many studies have examined how rheumatoid arthritis therapy affects the risk of metabolic comorbidities.
metabolic dysfunctionrheumatoid arthritisassessingcomplexinterplay
https://www.pharmaceutical-technology.com/data-insights/pegargiminase-polaris-pharmaceuticals-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/
Pegargiminase is under clinical development by Polaris Pharmaceuticals and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
metabolic dysfunctionpegargiminasepolarispharmaceuticalsassociated
https://www.everydayhealth.com/liver-disease/metabolic-dysfunction-associated-steatohepatitis/guide/
Sep 12, 2025 - MASH is a progressive form of liver disease that occurs when there’s an accumulation of fat in the liver. Learn more about risk factors, symptoms, and...
metabolic dysfunctionassociatedsteatohepatitismashsymptoms
https://www.pharmaceutical-technology.com/data-insights/da-1241-neurobo-pharmaceuticals-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/
DA-1241 is under clinical development by NeuroBo Pharmaceuticals and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
metabolic dysfunctiondapharmaceuticalsassociatedsteatohepatitis
https://pubmed.ncbi.nlm.nih.gov/40310463/
Metabolic dysfunction-associated steatohepatitis (MASH) represents a progressive form of steatotic liver disease which increases the risk for fibrosis and...
lipid dropletlivercholesterolcontentkey
https://www.mdpi.com/2072-6643/17/2/244
Metabolic dysfunction associated steatotic liver disease (MASLD) has been associated with increased risks of all-cause and cardiovascular disease (CVD)...
metabolic dysfunctionmagnesiumdepletionscoremortality
https://www.preprints.org/manuscript/202310.1615
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly termed nonalcoholic fatty liver disease (NAFLD), is a widespread global health...
thyroid hormonemitochondrial dysfunctiontherapeuticimplicationsmetabolic
https://www.mdpi.com/2072-6643/13/7/2128
Energy restriction is a first therapy in the treatment of obesity, but the underlying biological mechanisms have not been completely clarified. We analyzed the...
caloric restrictionmetabolic dysfunctionchangeshypothalamic
https://www.pharmaceutical-technology.com/data-insights/survodutide-boehringer-ingelheim-international-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/
Survodutide is under clinical development by Boehringer Ingelheim International and currently in Phase III for Metabolic Dysfunction-Associated Steatohepatitis...
boehringer ingelheimmetabolic dysfunctionsurvodutideinternationalassociated
https://liverfoundation.org/liver-diseases/veterans-information-center/metabolic-dysfunction-associated-steatotic-liver-disease-masld-and-liver-health-for-veterans/
Dec 1, 2025 - Metabolic dysfunction–associated steatotic liver disease (MASLD) is a liver condition characterized by fat accumulation in the liver linked to metabolic risk...
steatotic liver diseasemetabolic dysfunctionassociatedmasldhealth
https://pubmed.ncbi.nlm.nih.gov/40128809/
Parkinson's disease (PD) is a multi-system disorder characterized histopathologically by degeneration of dopaminergic neurons in the substantia nigra pars...
immune cellmetabolic dysfunctionparkinsondisease
https://pubmed.ncbi.nlm.nih.gov/40120772/
Hepatic stellate cells (HSCs) play a crucial role in the pathogenesis of liver fibrosis in metabolic dysfunction-associated steatohepatitis (MASH), a condition...
hepatic stellate cellmetabolic dysfunctionregulationphenotypesassociated
https://pubmed.ncbi.nlm.nih.gov/41225403/
Serum C3 is a promising diagnostic biomarker for MASLD in middle-aged and elderly adults, showing a distinct nonlinear relationship and strong discriminative...
diagnostic biomarkermetabolic dysfunctionserumcomplement
https://elifesciences.org/articles/29968
Store operated calcium entry is defective in hepatocytes of obese mice, and restoring this process is sufficient to improve glucose metabolism.
defectivestimmediatedstoreoperated
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=40186&ver=8&stateRegion=all&contractorNumber=all&proposedStatus=C&sortBy=commentStart&bc=11
Use this page to view details for the Local Coverage Determination for MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated...
biomarker testingrisk stratificationproposedlcdmetabolic
https://www.uea.ac.uk/course/phd-doctorate/phd-the-role-of-bilophila-wadsworthia-in-microbiome-driven-metabolic-dysfunction-impact-of-obesity-associated-microbiomes-narbadq25mmb
PhD The Role of Bilophila wadsworthia in Microbiome-Driven Metabolic Dysfunction: Impact of Obesity-Associated Microbiomes (NARBAD_Q25MMB) 2025/26 | UEA
bilophila wadsworthiaphdrolemicrobiomedriven
https://www.pharmaceutical-technology.com/data-insights/azemiglitazone-cirius-therapeutics-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/
Azemiglitazone is under clinical development by Cirius Therapeutics and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
metabolic dysfunctionazemiglitazoneciriustherapeuticsassociated